Skip to content
10-K

Annual Report

EPIRUS Biopharmaceuticals, Inc.

0001558370-16-004428

← back to feed
Filed
Mar 29, 2016 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2015 · Mar 25, 2016 26.18M sh
Capex FY 2015 · Dec 31, 2015 $477K
Capex FY 2015 · Dec 31, 2014 $217K
Short Term Debt FY 2015 · Dec 31, 2015 $14.83M
Cash And Equivalents FY 2015 · Dec 31, 2015 $31.52M
Cash And Equivalents FY 2015 · Dec 31, 2014 $21.46M
Cash And Equivalents restated FY 2015 · Dec 31, 2013 $1.8M
Stockholders Equity FY 2015 · Dec 31, 2015 $36.37M
Stockholders Equity FY 2015 · Dec 31, 2014 $32.4M
Stockholders Equity restated FY 2015 · Dec 31, 2013 −$39.38M
Current Liabilities FY 2015 · Dec 31, 2015 $33.28M
Current Liabilities FY 2015 · Dec 31, 2014 $7.38M
Total Liabilities FY 2015 · Dec 31, 2015 $35.9M
Total Liabilities FY 2015 · Dec 31, 2014 $18.98M
Current Assets FY 2015 · Dec 31, 2015 $35.25M
Current Assets FY 2015 · Dec 31, 2014 $23.02M
Total Assets FY 2015 · Dec 31, 2015 $72.26M
Total Assets restated FY 2015 · Dec 31, 2014 $51.38M
Sga Expense FY 2015 · Dec 31, 2015 $21.95M
Sga Expense FY 2015 · Dec 31, 2014 $22.97M
Rd Expense FY 2015 · Dec 31, 2015 $30.93M
Rd Expense FY 2015 · Dec 31, 2014 $16.29M
Net Income FY 2015 · Dec 31, 2015 −$52.19M
Net Income FY 2015 · Dec 31, 2015 −$138.76M
Net Income FY 2015 · Dec 31, 2014 −$41.84M
Operating Income FY 2015 · Dec 31, 2015 −$52.3M
Operating Income FY 2015 · Dec 31, 2014 −$39.26M
Cost Of Revenue FY 2015 · Dec 31, 2015 $125K
Stock Repurchased FY 2015 · Dec 31, 2014 $297K
Long Term Debt restated FY 2015 · Dec 31, 2014 $7.27M